Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Non-Current Deffered Revenue: 2019-2023

Historic Non-Current Deffered Revenue for Legend Biotech (LEGN) over the last 4 years, with Dec 2023 value amounting to $48.0 million.

  • Legend Biotech's Non-Current Deffered Revenue rose 4.76% to $6.9 million in Q2 2025 from the same period last year, while for Jun 2025 it was $6.9 million, marking a year-over-year increase of 4.76%. This contributed to the annual value of $48.0 million for FY2023, which is N/A change from last year.
  • As of FY2023, Legend Biotech's Non-Current Deffered Revenue stood at $48.0 million, which was up 119.77% from -$242.6 million recorded in FY2021.
  • Legend Biotech's 5-year Non-Current Deffered Revenue high stood at $277.8 million for FY2019, and its period low was -$242.6 million during FY2021.
  • For the 2-year period, Legend Biotech's Non-Current Deffered Revenue averaged around -$97.3 million, with its median value being -$97.3 million (2021).
  • Data for Legend Biotech's Non-Current Deffered Revenue shows a maximum YoY tumbled of 188.19% (in 2021) over the last 5 years.
  • Yearly analysis of 4 years shows Legend Biotech's Non-Current Deffered Revenue stood at $277.8 million in 2019, then dropped by 0.97% to $275.1 million in 2020, then slumped by 188.19% to -$242.6 million in 2021, then reached $48.0 million in 2023.